by Jordana Choucair | Mar 21, 2022 | Life Sciences
A new study published in JAMA Network Open found that the Johnson & Johnson (J&J) COVID-19 vaccine remains durable and effective. According to the research, the J&J shot was 76 percent effective in preventing COVID-19 infections and 81 percent effective in...
by Jordana Choucair | Mar 21, 2022 | Life Sciences
AstraZeneca announced its antibody-based cocktail to prevent and treat COVID-19 retained neutralizing activity against Omicron COVID-19 variants, including the BA.2 sub-variant. Britain’s drug regulator approved the therapy, called Evusheld, last week for preventing...
by Jordana Choucair | Mar 21, 2022 | Mental Health
The American Psychiatric Association (APA) added prolonged grief disorder in its latest edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM). Its inclusion means that clinicians can now bill insurance companies for treating people for the...
by Jordana Choucair | Mar 21, 2022 | Public Health/Prevention
Dr. Anthony Fauci said that the U.S. should expect an increase in COVID-19 cases from the BA.2 variant. He predicted the “uptick” will be similar to the current increase in Europe, despite the current decline in cases, hospitalizations, and deaths in the U.S. However,...
by Jordana Choucair | Mar 18, 2022 | Health IT
GE Healthcare launched its new Edison Digital Health Platform for health care organizations. The platform aggregates applications and patient data from multiple sources and integrates them with existing clinical workflows for easy provider access. It also includes a...
by Jordana Choucair | Mar 18, 2022 | Life Sciences
The Medicines Patent Pool (MPP), a U.N.-backed organization, announced that 35 manufacturers agreed to produce generic forms of Paxlovid – Pfizer’s oral antiviral treatment for COVID-19. Six companies will focus on producing the substance of the drug, nine...
Recent Comments